HC Wainwright Brokers Boost Earnings Estimates for BioCardia

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright raised their FY2025 earnings estimates for shares of BioCardia in a report issued on Thursday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.25) for the year, up from their previous estimate of ($1.38). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.56) EPS and FY2028 earnings at ($0.38) EPS.

Other equities analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, October 8th. Zacks Research raised BioCardia to a “hold” rating in a research note on Tuesday, September 23rd. Finally, Wall Street Zen upgraded BioCardia to a “sell” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, BioCardia currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

BioCardia Stock Performance

BioCardia stock opened at $1.29 on Monday. The firm has a market cap of $13.69 million, a price-to-earnings ratio of -0.70 and a beta of 0.78. BioCardia has a 1 year low of $1.00 and a 1 year high of $3.20. The firm’s 50 day moving average price is $1.43 and its two-hundred day moving average price is $1.90.

BioCardia (NASDAQ:BCDA) last released its earnings results on Wednesday, November 12th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01.

Insider Buying and Selling

In other BioCardia news, Director Simon H. Stertzer acquired 398,400 shares of the firm’s stock in a transaction on Friday, September 19th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $498,000.00. Following the transaction, the director owned 591,054 shares of the company’s stock, valued at $738,817.50. The trade was a 206.80% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Scott Blank bought 288,000 shares of the stock in a transaction on Friday, September 19th. The shares were acquired at an average cost of $1.25 per share, for a total transaction of $360,000.00. Following the purchase, the director owned 634,023 shares in the company, valued at approximately $792,528.75. This represents a 83.23% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 735,100 shares of company stock valued at $919,281. Corporate insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioCardia stock. Cetera Investment Advisers purchased a new position in shares of BioCardia, Inc. (NASDAQ:BCDA) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned approximately 0.37% of BioCardia at the end of the most recent reporting period. Institutional investors own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.